Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis. - Covington N; Luetkemeyer AF; Imperial MZ; Dawson R; Cramer Y; Rosenkranz S; Swindells S; Gelmanova I; Avihingsanon A; Arduino RC; Samaneka W; Dooley KE; et al. (Pharmacogenetics and genomics, 2025)